M. D. Anderson Cancer Center SPORE in Multiple Myeloma

M.D. 安德森癌症中心 SPORE 治疗多发性骨髓瘤

• 批准号: 8543577
• 负责人: ROBERT ZYGMUNT ORLOWSKI
• 金额: $ 215.05万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-22 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8543577
• 关键词: Accounting; Adoptive Immunotherapy; Agonist; Animal Model; Antibodies; Apoptotic; Appointment; Autologous; BCL2 gene; BIK gene; Basic Science; Berry; Bioinformatics; Biological Models; Biology; Biometry; Biostatistics Core; Cancer Center; Cancer Center Support Grant; Cell Death; Cell physiology; Cells; Cessation of life; Chairperson; Characteristics; Chemosensitization; Clinic; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Clinical Trials Design; Collaborations; Communities; Comprehensive Cancer Center; Conceptions; Core Facility; Correlative Study; Cyclin-Dependent Kinase Inhibitor; Cytokine Receptors; DNA analysis; Data; Databases; Dendritic Cells; Development; Disease; Doctor of Medicine; Doctor of Philosophy; Drug resistance; Electron Microscopy Facility; Flow Cytometry; Fostering; Gap Junctions; Gene Expression Profiling; Generations; Goals; Grant; Growth; Head; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; High Dose Chemotherapy; Histopathology Facility; Immune response; Immunoglobulin Idiotypes; Immunologics; Immunotherapy; In Vitro; K-Series Research Career Programs; Keyhole Limpet Hemocyanin; Learning; Lymphoma; MCL1 protein; Malignant Neoplasms; Medicine; Membrane Microdomains; Molecular; Monitor; Monoclonal Antibodies; Morbidity - disease rate; Multiple Myeloma; Outcome; PMAIP1 gene; Paraproteins; Pathology; Pathway interactions; Patients; Pennsylvania; Pharmaceutical Preparations; Phase; Physiological; Plasma Cells; Play; Preparation; Principal Investigator; Process; Progress Reports; Protein Array; Protocols documentation; Quality of life; Refractory; Refractory Disease; Regimen; Relapse; Reporting; Research; Research Personnel; Residual Neoplasm; Resource Sharing; Resources; Role; Sampling; Sampling Studies; Schedule; Science; Services; Source; Specialized Program of Research Excellence; Structure; System; T cell therapy; T-Lymphocyte; Teleconferences; Testing; Therapeutic; Therapeutic Agents; Therapeutic Clinical Trial; Tissues; Toxic effect; Training; Translating; Translational Research; Translations; Transplantation; Type I Epithelial Receptor Cell; United States; Universities; University of Texas M D Anderson Cancer Center; Vaccination; Vaccine Therapy; Vaccines; Virginia; Work; X-linked IAP; Yang; base; bench to bedside; cancer therapy; career development; cellular imaging; chemosensitizing agent; clinically relevant; design; experience; improved; in vivo; in vivo Model; inhibitor/antagonist; innovation; insight; mTOR protein; meetings; mortality; multicatalytic endopeptidase complex; multidisciplinary; mutant; neoplastic cell; next generation; novel; novel strategies; novel therapeutics; pre-clinical; professor; programs; receptor; reconstitution; research and development; research facility; small molecule; success; ubiquitin-protein ligase

Multiple myeloma is a clonal plasma cell malignancy which, despite recent treatment advances, remains incurable in the vast majority of the over 59,000 patients in the United States afflicted with this disease. Therefore, The University of Texas M. D. Anderson Cancer Center, in collaboration with The University of Pennsylvania and the Virginia Commonwealth University, is proposing this Specialized Program of Research Excellence (SPORE) in Multiple Myeloma. The primary goal of this program will be to translate promising new strategies from the bench to the bedside to reduce the morbidity and mortality, and improve the quality of life of multiple myeloma patients. To do so, a multidisciplinary, collaborative group of experienced investigators will be pursuing four highly innovative Projects: Project 1 - Combination Activated T-Cell and Vaccine Therapy in Myeloma (Kwak/Giralt/June/Stadtmauer) Project 2 - Anti-(32-microglobulin Antibodies as Therapeutic Agents for Multiple Myeloma (Yi/Wang) Project 3-Targeting the HDM-2 E3 Ligase in Multiple Myeloma (Orlowski/Weber) Project 4 - Targeting Multiple Myeloma by Combining CDK Inhibitors and Bcl-2 Antagonists (Grant/Wang/Dai/Dent) To provide the specialized expertise needed to maximize the success of the Projects, they will be supported by five Core Facilities: Core A - Administrative Core Facility (Orlowski/Kwak) Core B - Myeloma Tissue Core Facility (Kornblau/Wang/Davis/Lin) Core C - Animal Models Core Facility (Yi/Yang) Core D - Clinical Trials Core Facility (Weber/Stadtmauer/McLaughlin) Core E - Biostatistics and Bioinformatics Core Facility (Berry/Baladandayuthapani/Almeida/ Ramakrishnan) Also, the SPORE will attract new investigators with additional novel ideas, and train the next generation of myeloma researchers, through the following Programs: Developmental Research Program (OrlowskiA'i) Career Development Program (Kwak/Aggarwal/Stadtmauer) This SPORE will therefore serve as a nexus for its Investigators and the myeloma research community to foster the kind of multidisciplinary efforts that are necessary to bring us closer to a cure for this disease.

多发性骨髓瘤是一种克隆浆细胞恶性肿瘤，尽管最近的治疗取得了进展，但在美国59,000多名患有这种疾病的患者中，绝大多数人仍然无法治愈。因此，德克萨斯大学m.d.安德森癌症中心与宾夕法尼亚大学和弗吉尼亚联邦大学合作，提出了这个多发性骨髓瘤卓越研究专业项目（SPORE）。该项目的主要目标是将有希望的新策略从实验台上转化为床边，以降低多发性骨髓瘤患者的发病率和死亡率，并改善患者的生活质量。为此，一个由经验丰富的研究人员组成的多学科合作小组将开展四个高度创新的项目：